,address1,city,zip,country,phone,fax,website,longBusinessSummary,companyOfficers,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,5 Badner Street,Ramat Gan,5218102,Israel,972 3 611 6600,972 9 951 9708,https://www.xtlbio.com,"XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.","{'maxAge': 1, 'name': 'Mr. Shlomo Spokone Shalev', 'age': 60, 'title': 'CEO & Director', 'yearBorn': 1962, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,3.6,3.6,3.7,3.7,3.6,3.6,3.7,3.7,0.839428,14000,14000,760764,535839,535839,3.6,3.8,2000000,379200,19025622,0.03,3.7,0.03486,0.041815,0.0,0.0,ILA,17233622,0.0,413256823,514206016,0.1196,0.0,0.005,740.0,1672444800,1703980800,1688083200,-2852000,-0.0,-20.467,TLV,EQUITY,XTLB.TA,XTLB.TA,XTL BIO,XTL Biopharmaceuticals Ltd.,1125383400,Asia/Jerusalem,IDT,10800000,3.7,none,2383000,0.004,-842000,0,14.62,15.344,-0.12199,-0.6888,0.0,0.0,0.0,USD,
1,5 Badner Street,Ramat Gan,5218102,Israel,972 3 611 6600,972 9 951 9708,https://www.xtlbio.com,"XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.","{'maxAge': 1, 'name': 'Mr. Itay  Weinstein', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",86400,4,3.6,3.6,3.7,3.7,3.6,3.6,3.7,3.7,0.839428,14000,14000,760764,535839,535839,3.6,3.8,2000000,379200,19025622,0.03,3.7,0.03486,0.041815,0.0,0.0,ILA,17233622,0.0,413256823,514206016,0.1196,0.0,0.005,740.0,1672444800,1703980800,1688083200,-2852000,-0.0,-20.467,TLV,EQUITY,XTLB.TA,XTLB.TA,XTL BIO,XTL Biopharmaceuticals Ltd.,1125383400,Asia/Jerusalem,IDT,10800000,3.7,none,2383000,0.004,-842000,0,14.62,15.344,-0.12199,-0.6888,0.0,0.0,0.0,USD,
